Professor Li received his PhD degree from National Yamaguchi University (Japan) in 1997. Dr. Li is currently the head of the research team of the SKORG, Shanghai Cancer Institute. He has been focusing on cancer stem cells (CSCs), signaling transduction, mechanism of tumor metastasis, drug resistance and pre-clinical researches for hepatocellular carcinoma. He has undertaken 6 NSFC General Projects, Eleventh, 12th and 13th Five-Year Plan National Science and Technology Major Special Projects of each category one projects, currently undertaking 2 general projects of NSFC. From 2011 to 2020, Dr. Li had published 74 SCI papers (including 35 papers as corresponding author, including 2 Hepatology, 1 Biomaterials, 3 Cancer Res, 1 Oncogene, 1 J Exp Clin Cancer Res journal papers), and participated in the editing of 3 books. He has gotten 11 authorized national invention patents. He enjoyed the special allowance of the State Council in 2006. In 2009, he was selected as the municipal outstanding academic leader training program (A), the local training program for leading talents in Shanghai, and the national talent training program for the "New Century Talent Project". Dr. Li is Member of the 12th and 13th Shanghai Committee of the Chinese People's Political Consultative Conference (CPPCC).

Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X, Ge C, Zhao F, Chen T, Xie H, Cui Y, Tian H, Li H, Yao M, Li J#. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene. 41(17):2492-2504, 2022.

Xiaoxia Chen, Tianshu Chen, Lili Zhang, Zhenyu Wang, Qingqing Zhou, Tingting Huang, Chao Ge, Huili Xu, Miaoxin Zhu, Fangyu Zhao, Ming Yao, Hua Tian, Hong Li, Xiaoli Zhu#, Jinjun Li#. Cyclodextrin-Mediated Formation of Porous RNA Nanospheres and Their Application in Synergistic Targeted Therapeutics of Hepatocellular Carcinoma. Biomaterials 261:120304, 2020

Zhang L*, Huo Q*, Ge C, Zhao F, Zhou Q, Chen X, Tian H, Chen T, Xie H, Cui Y, Yao M, Li H#, Li J#. ZNF143-mediated H3K9 trimethylation upregulates CDC6 by activating MDIG in hepatocellular carcinoma. Cancer Res 80(12): 2599-611, 2020

Jing Yang*, Lili Zhang*, Zhiyuan Jiang, Chao Ge, Fangyu Zhao, Jingyi Jiang, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, Ming Yao, Hong Li, Jinjun Li#. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics 9(20): 5810-5827, 2019

Cong Chen, Chao Ge, Zheng Liu, Liangyu Li, Fangyu Zhao, Hua Tian, Taoyang Chen, Hong Li, Ming Yao, Jinjun Li#. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression. J Exp Clin Cancer Res 37(1):263, 2018

Huo Q, Ge C, Tian H, Sun J, Cui M, Li H, Zhao F, Chen T, Xie H, Cui Y, Yao M, Li J#. Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis. 8(5):e2766, 2017

Zhang L, Ge C, Zhao F, Zhang Y, Wang X, Yao M, Li J#. NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling. Cancer Res 76(23): 7059-71, 2016

Hua Tian, Chao Ge, Hong Li, Fangyu Zhao, Helei Hou, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li#. Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma. Hepatology 59(4): 1459-1470, 2014

Lixing Zhang, Hefen Sun, Fangyu Zhao, Ping Lu, Chao Ge, Hong Li, Helei Hou, Mingxia Yan, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Xiaowu Huang, Jia Fan, Ming Yao, Jinjun Li#. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocelluar carcinoma. Cancer Res 72(16): 4276-4285, 2012

Hong Li, Chao Ge, Fangyu Zhao, Mingxia Yan, Chen Hu, Deshui Jia, Hua Tian, Miaoxin Zhu,Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Jianren Gu, Hong Tu, Xianghuo He, Ming Yao, Yongzhong Liu, Jinjun Li#. HIF-1α-activated ANGPTL4 contributes to tumor metastasis via VCAM-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology 54(3): 910-919, 2011